Third Harmonic Bio to Participate in the 44th Annual TD Cowen Health Care Conference
- None.
- None.
SAN FRANCISCO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced that Chief Executive Officer, Natalie Holles, will participate in a fireside chat at the 44th Annual TD Cowen Health Care Conference on Tuesday, March 5, 2024, at 1:30 p.m. ET.
A live audio webcast will be available within the Investors & Media section of the Third Harmonic Bio website. An archived replay will be accessible for 90 days following the event.
About Third Harmonic Bio, Inc.
Third Harmonic Bio is a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases through the development of novel highly selective, small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Early clinical studies demonstrate that KIT inhibition has the potential to revolutionize the treatment of a broad range of mast-cell-mediated inflammatory diseases, and that a titratable, oral, intracellular small molecule inhibitor may provide the optimal therapeutic profile against this target. Third Harmonic Bio’s lead product candidate, THB335, is a titratable, oral, intracellular small molecule inhibitor expected to enter clinical trials during the first half of 2024. For more information, please visit the Third Harmonic Bio website: www.thirdharmonicbio.com.
Investor and Media Contact:
Lori Murray
lori.murray@thirdharmonicbio.com
FAQ
When will Natalie Holles participate in the fireside chat at the 44th Annual TD Cowen Health Care Conference?
Where can investors access the live audio webcast of the event?
For how long will the archived replay of the event be accessible?
